title: Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
abstract: BACKGROUND
  The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity.
  
  
  OBJECTIVE
  To evaluate the product of PGAxBSA as a sensitive alternative to the Psoriasis Area and Severity Index (PASI) for assessing disease severity and therapeutic response with data collected from the phase 3 ESTEEM 1 and 2 trials.
  
  
  METHODS
  This post hoc analysis included 836 patients randomized to apremilast 30 mg BID at baseline (ESTEEM 1, n=562; ESTEEM 2, n=274). Spearman correlation coefficients were used to compare PGAxBSA, PASI, and the Dermatology Life Quality Index (DLQI). Concordance between PGAxBSA and PASI was evaluated for 50%/75%/90% improvement from baseline at week 16.
  
  
  RESULTS
  In ESTEEM 1 and 2, PGAxBSA and PASI exhibited significant positive correlations for measuring disease severity at baseline (r≥0.757) and week 16 (r≥0.807). At week 16, ≥79% concordance was observed between PGAxBSA and PASI for 75% and 90% improvement from baseline; greater concordance (>88.0%) was observed using 50% improvement from baseline. At week 16, PGAxBSA and PASI were moderately correlated with DLQI.
  
  
  CONCLUSIONS
  Analysis was limited to patients with baseline BSA ≥10% and static PGA ≥3.
  
  
  CONCLUSIONS
  In patients with moderate to severe psoriasis, PGAxBSA is correlated with PASI and sensitive to therapeutic response. <p><em>J Drugs Dermatol. 2017;16(2):147-153.</em></p>.
authors.forename: Kristina C
authors.initials: KC
authors.lastname: Duffin
authors.forename: Kim A
authors.initials: KA
authors.lastname: Papp
authors.forename: Jerry
authors.initials: J
authors.lastname: Bagel
authors.forename: Eugenia
authors.initials: E
authors.lastname: Levi
authors.forename: Rongdean
authors.initials: R
authors.lastname: Chen
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019985:Benchmarking; D001830:Body Surface Area; D003880:Dermatology / Q000592:standards; D005260:Female; D014943:Global Health; D006801:Humans; D008297:Male; D008875:Middle Aged; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058988:Phosphodiesterase 4 Inhibitors; D013792:Thalidomide; C505730:apremilast